Francesco Lanza, MD, Ravenna Hospital, Ravenna, Italy, outlines the sequential use of novel monoclonal antibodies for the treatment of adult acute lymphoblastic leukemia (ALL) who are relapsed/refractory to chemotherapy, including blinatumomab, a CD19 targeting monoclonal antibody, as well as inotuzumab ozogamicin, an antibody-drug conjugate. Dr Lanza also discusses the sequential use of CAR T-cell based therapies in combination with monoclonal antibodies and controversy surrounding this treatment approach. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).